

Diane P Hanger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3853686/publications.pdf>

Version: 2024-02-01

99
papers

9,946
citations

41344

49
h-index

45317

90
g-index

122
all docs

122
docs citations

122
times ranked

10590
citing authors

#	ARTICLE	IF	CITATIONS
1	The Disease Associated Tau35 Fragment has an Increased Propensity to Aggregate Compared to Full-Length Tau. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 779240.	3.5	8
2	HCN channelopathy couples disease-associated tau to synaptic dysfunction. <i>Alzheimer's and Dementia</i> , 2021, 17, e058346.	0.8	1
3	Autophagy and lysosomal defects in cells expressing disease-associated tau. <i>Alzheimer's and Dementia</i> , 2021, 17, e058299.	0.8	1
4	Defects in the autophagy lysosomal pathway in a cell model of disease-associated tau. <i>Alzheimer's and Dementia</i> , 2021, 17, e051303.	0.8	0
5	Self-assembly and cellular effect of tau35, a disease-associated tau fragment.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e052072.	0.8	0
6	Considerations for future tau-targeted therapeutics: can they deliver?. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 265-267.	5.0	11
7	Editorial: Tau Propagation Mechanisms: Cell Models, Animal Models, and Beyond. <i>Frontiers in Neuroscience</i> , 2020, 14, 456.	2.8	1
8	Bridging integrator 1 protein loss in Alzheimer's disease promotes synaptic tau accumulation and disrupts tau release. <i>Brain Communications</i> , 2020, 2, .	3.3	18
9	A pathogenic tau fragment compromises microtubules, disrupts insulin signaling and induces the unfolded protein response. <i>Acta Neuropathologica Communications</i> , 2019, 7, 2.	5.2	16
10	Synaptic Localisation of Tau. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1184, 105-112.	1.6	16
11	The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 5125-5136.	4.0	15
12	Characterisation of tau in the human and rodent enteric nervous system under physiological conditions and in tauopathy. <i>Acta Neuropathologica Communications</i> , 2018, 6, 65.	5.2	32
13	A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies. <i>Acta Neuropathologica Communications</i> , 2018, 6, 37.	5.2	44
14	The ER-Mitochondria Tethering Complex VAPB-PTPIP51 Regulates Autophagy. <i>Current Biology</i> , 2017, 27, 371-385.	3.9	287
15	Î±-Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca ²⁺ homeostasis and mitochondrial ATP production. <i>Acta Neuropathologica</i> , 2017, 134, 129-149.	7.7	262
16	Roles of tau protein in health and disease. <i>Acta Neuropathologica</i> , 2017, 133, 665-704.	7.7	639
17	Membrane association and release of wild-type and pathological tau from organotypic brain slice cultures. <i>Cell Death and Disease</i> , 2017, 8, e2671-e2671.	6.3	50
18	Hippocampal neurophysiology is modified by a disease-associated C-terminal fragment of tau protein. <i>Neurobiology of Aging</i> , 2017, 60, 44-56.	3.1	26

#	ARTICLE	IF	CITATIONS
19	Inhibition of glycogen synthase kinase-3 by BTA-EG4 reduces tau abnormalities in an organotypic brain slice culture model of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 7434.	3.3	20
20	[P1-223]: FUNCTIONAL ROLES FOR TAO KINASES IN THE DEVELOPMENT OF TAU PATHOLOGY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P328.	0.8	0
21	[F3-07-03]: ACTIVITY-DEPENDENT TAU RELEASE: IMPLICATIONS FOR TAU PROPAGATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P888.	0.8	0
22	<scp>ALS</scp> / <scp>FTD</scp> associated <scp>FUS</scp> activates <scp>GSK</scp> β to disrupt the <scp>VAPB</scp> β <scp>PTPIP</scp> 51 interaction and <scp>ER</scp> β mitochondria associations. <i>EMBO Reports</i> , 2016, 17, 1326-1342.	4.5	201
23	Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2016, 4, 49.	5.2	60
24	P1-155: Post-Mortem Brain Tissue Characterisation of Inflammatory and Pathological Hallmarks of Alzheimer's Disease During Disease Progression. <i>Alzheimer's and Dementia</i> , 2016, 12, P462.	0.8	0
25	Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain. <i>Acta Neuropathologica Communications</i> , 2016, 4, 34.	5.2	100
26	Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate. <i>Brain</i> , 2016, 139, 2290-2306.	7.6	43
27	Mislocalization of neuronal tau in the absence of tangle pathology in phosphomutant tau knockin mice. <i>Neurobiology of Aging</i> , 2016, 39, 1-18.	3.1	23
28	Reduced number of axonal mitochondria and tau hypophosphorylation in mouse P301L tau knockin neurons. <i>Neurobiology of Disease</i> , 2016, 85, 1-10.	4.4	57
29	P3-054: The amyloid-binding agent bta-eg4 reduces pathological tau species in a novel organotypic 3xTg-AD brain slice culture model that recapitulates key in vivo degenerative phenotypes. , 2015, 11, P639-P639.		0
30	Modification of the <i>Drosophila</i> model of in vivo Tau toxicity reveals protective phosphorylation by GSK β . <i>Biology Open</i> , 2014, 3, 1-11.	1.2	27
31	Calpain cleavage and inactivation of the sodium calcium exchanger β occur downstream of β in Alzheimer's disease. <i>Aging Cell</i> , 2014, 13, 49-59.	6.7	38
32	Intracellular and Extracellular Roles for Tau in Neurodegenerative Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 40, S37-S45.	2.6	45
33	A role for tau at the synapse in Alzheimer's disease pathogenesis. <i>Neuropharmacology</i> , 2014, 76, 1-8.	4.1	160
34	Astrocytes and neuroinflammation in Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2014, 42, 1321-1325.	3.4	76
35	P1-115: IDENTIFICATION OF THE BINDING SITE BETWEEN TAU AND FYN: CONSEQUENCES FOR TAU RELEASE?. , 2014, 10, P343-P343.		0
36	P1-116: ASTROCYTE ACTIVATION INFLUENCES THE DEVELOPMENT OF TAUOPATHY. , 2014, 10, P343-P343.		0

#	ARTICLE	IF	CITATIONS
37	Physiological release of endogenous tau is stimulated by neuronal activity. <i>EMBO Reports</i> , 2013, 14, 389-394.	4.5	510
38	Tau phosphorylation affects its axonal transport and degradation. <i>Neurobiology of Aging</i> , 2013, 34, 2146-2157.	3.1	136
39	Prostate-derived Sterile 20-like Kinases (PSKs/TAOKs) Phosphorylate Tau Protein and Are Activated in Tangle-bearing Neurons in Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2013, 288, 15418-15429.	3.4	49
40	The Importance of Tau Phosphorylation for Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2013, 4, 83.	2.4	312
41	NUB1 modulation of GSK3 β reduces tau aggregation. <i>Human Molecular Genetics</i> , 2012, 21, 5254-5267.	2.9	29
42	Dynamic association of tau with neuronal membranes is regulated by phosphorylation. <i>Neurobiology of Aging</i> , 2012, 33, 431.e27-431.e38.	3.1	117
43	Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a τ knockin mouse. <i>Neurobiology of Aging</i> , 2012, 33, 621.e1-621.e15.	3.1	75
44	Key issues in the acquisition and analysis of qualitative and quantitative mass spectrometry data for peptide-centric proteomic experiments. <i>Amino Acids</i> , 2012, 43, 1075-1085.	2.7	16
45	Functional Implications of Glycogen Synthase Kinase-3-Mediated Tau Phosphorylation. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-11.	2.0	82
46	Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau. <i>FEBS Journal</i> , 2011, 278, 2927-2937.	4.7	78
47	Advances in tau-based drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 797-810.	5.0	39
48	Astrocytes are important mediators of A β -induced neurotoxicity and tau phosphorylation in primary culture. <i>Cell Death and Disease</i> , 2011, 2, e167-e167.	6.3	304
49	Functional implications of the association of tau with the plasma membrane. <i>Biochemical Society Transactions</i> , 2010, 38, 1012-1015.	3.4	64
50	Isolation of detergent resistant microdomains from cultured neurons: detergent dependent alterations in protein composition. <i>BMC Neuroscience</i> , 2010, 11, 120.	1.9	24
51	Anti-Inflammatory Impact of Minocycline in a Mouse Model of Tauopathy. <i>Frontiers in Psychiatry</i> , 2010, 1, 136.	2.6	91
52	Tau cleavage and tau aggregation in neurodegenerative disease. <i>Biochemical Society Transactions</i> , 2010, 38, 1016-1020.	3.4	51
53	Transgenic Mouse Models of Tauopathy in Drug Discovery. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 403-428.	1.4	36
54	Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfolding. <i>Prion</i> , 2009, 3, 78-83.	1.8	59

#	ARTICLE	IF	CITATIONS
55	Quantitation of glycogen synthase kinase-3 sensitive proteins in neuronal membrane rafts. <i>Proteomics</i> , 2009, 9, 3022-3035.	2.2	9
56	Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. <i>FASEB Journal</i> , 2009, 23, 739-750.	0.5	113
57	Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. <i>Trends in Molecular Medicine</i> , 2009, 15, 112-119.	6.7	778
58	Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1647-1666.	2.8	82
59	The Microtubule-Associated Protein Tau is Also Phosphorylated on Tyrosine. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 1-9.	2.6	75
60	Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats. <i>Journal of Neurochemistry</i> , 2008, 105, 2343-2352.	3.9	73
61	The microtubule-associated protein tau is phosphorylated by Syk. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2008, 1783, 188-192.	4.1	46
62	Membrane-bound amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism. <i>FASEB Journal</i> , 2008, 22, 1552-1559.	0.5	114
63	Phosphorylation Regulates Tau Interactions with Src Homology 3 Domains of Phosphatidylinositol 3-Kinase, Phospholipase C β 1, Grb2, and Src Family Kinases. <i>Journal of Biological Chemistry</i> , 2008, 283, 18177-18186.	3.4	198
64	Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. <i>FASEB Journal</i> , 2008, 22, 3186-3195.	0.5	142
65	Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis. <i>Journal of Biological Chemistry</i> , 2007, 282, 23645-23654.	3.4	387
66	Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. <i>Journal of Neurochemistry</i> , 2007, 103, 1132-1144.	3.9	158
67	Kinase activities increase during the development of tauopathy in htau mice. <i>Journal of Neurochemistry</i> , 2007, 103, 2256-2267.	3.9	69
68	Molecular motors implicated in the axonal transport of tau and β -synuclein. <i>Journal of Cell Science</i> , 2005, 118, 4645-4654.	2.0	141
69	Tyrosine 394 Is Phosphorylated in Alzheimer's Paired Helical Filament Tau and in Fetal Tau with c-Abl as the Candidate Tyrosine Kinase. <i>Journal of Neuroscience</i> , 2005, 25, 6584-6593.	3.6	168
70	Quantitative analysis of tau isoform transcripts in sporadic tauopathies. <i>Molecular Brain Research</i> , 2005, 137, 104-109.	2.3	60
71	The ultrastructural distribution of alpha-synuclein-like protein in normal mouse brain. <i>Brain Research</i> , 2004, 1004, 61-72.	2.2	58
72	P3-258 Molecular motors implicated in the fast axonal transport of tau. <i>Neurobiology of Aging</i> , 2004, 25, S428.	3.1	0

#	ARTICLE	IF	CITATIONS
73	Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. <i>Molecular Brain Research</i> , 2004, 121, 95-101.	2.3	20
74	Parkinson's disease α -synuclein mutations exhibit defective axonal transport in cultured neurons. <i>Journal of Cell Science</i> , 2004, 117, 1017-1024.	2.0	163
75	Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. <i>Neuropathology and Applied Neurobiology</i> , 2003, 29, 288-302.	3.2	194
76	Familial Danish Dementia: A Novel Form of Cerebral Amyloidosis Associated with Deposition of Both Amyloid-Dan and Amyloid-Beta. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 254-267.	1.7	116
77	The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies. <i>FEBS Letters</i> , 2002, 531, 538-542.	2.8	52
78	Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. <i>Brain</i> , 2002, 125, 969-975.	7.6	80
79	Autopsy-Confirmed Familial Early-Onset Alzheimer Disease Caused by the L153V Presenilin 1 Mutation. <i>Archives of Neurology</i> , 2001, 58, 953.	4.5	26
80	Sites of phosphorylation in tau and factors affecting their regulation. <i>Biochemical Society Symposia</i> , 2001, 67, 73-80.	2.7	91
81	Induction of neuronal death by α -synuclein. <i>European Journal of Neuroscience</i> , 2000, 12, 3073-3077.	2.6	151
82	Chicken synucleins: cloning and expression in the developing embryo. <i>Mechanisms of Development</i> , 2000, 99, 195-198.	1.7	19
83	New Phosphorylation Sites Identified in Hyperphosphorylated Tau (Paired Helical Filament-Tau) from Alzheimer's Disease Brain Using Nano-electrospray Mass Spectrometry. <i>Journal of Neurochemistry</i> , 1998, 71, 2465-2476.	3.9	330
84	Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease. <i>Neuroscience Letters</i> , 1997, 230, 49-52.	2.1	97
85	Oxidative Stress Induces Dephosphorylation of τ , in Rat Brain Primary Neuronal Cultures. <i>Journal of Neurochemistry</i> , 1997, 68, 1590-1597.	3.9	49
86	Neurodegenerative changes including altered tau phosphorylation and neurofilament immunoreactivity in mice transgenic for the serine/threonine kinase mos. <i>Neurobiology of Aging</i> , 1996, 17, 235-241.	3.1	24
87	Pathological lesions of Alzheimer's disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome. <i>Neuroscience Letters</i> , 1996, 219, 167-170.	2.1	53
88	PHOSPHORYLATION OF TAU BY GLYCOGEN SYNTHASE KINASE-3 ² IN VITRO PRODUCES SPECIES WITH SIMILAR ELECTROPHORETIC AND IMMUNOGENIC PROPERTIES TO PHF-TAU FROM ALZHEIMERS DISEASE BRAIN. <i>Biochemical Society Transactions</i> , 1995, 23, 45S-45S.	3.4	1
89	Modulation of PHF-like tau phosphorylation in cultured neurones and transfected cells. <i>Neurobiology of Aging</i> , 1995, 16, 389-397.	3.1	41
90	Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. <i>Current Biology</i> , 1994, 4, 1077-1086.	3.9	448

#	ARTICLE	IF	CITATIONS
91	PHF-tau from Alzheimer's brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase-3 ^β . FEBS Letters, 1994, 349, 359-364.	2.8	92
92	Phosphorylation of Tau by Cyclic-AMP-Dependent Protein Kinase. Dementia and Geriatric Cognitive Disorders, 1993, 4, 256-263.	1.5	21
93	Molecular pathology of Alzheimer's disease in sporadic and familial Alzheimer's disease with mutations in the amyloid precursor protein. Biochemical Society Transactions, 1992, 20, 642-645.	3.4	7
94	Tau pathology in a case of familial Alzheimer's disease with a valine to glycine mutation at position 717 in the amyloid precursor protein. Neuroscience Letters, 1992, 145, 178-180.	2.1	23
95	Familial Alzheimer's disease with the amyloid precursor protein position 717 mutation and sporadic Alzheimer's disease have the same cytoskeletal pathology. Neuroscience Letters, 1992, 137, 221-224.	2.1	87
96	Familial Alzheimer's disease with an APP717 point mutation and sporadic Alzheimer's disease have the same cytoskeletal pathology. Neurobiology of Aging, 1992, 13, S57.	3.1	1
97	Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase. Neuroscience Letters, 1992, 147, 58-62.	2.1	690
98	Characterization of a Partial cDNA Specific for the High Molecular Weight Microtubule-Associated Protein MAP2 That Encodes Epitopes Shared with Paired Helical Filaments of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1990, 1, 304-315.	1.5	1
99	Fluconazole and testosterone: in vivo and in vitro studies. Antimicrobial Agents and Chemotherapy, 1988, 32, 646-648.	3.2	46